Biocon Ltd. informed in a filing that the USFDA has conducted a pre-approval inspection (PAI) of an oral solid dosage manufacturing facility of Biocon Pharma Ltd., which was triggered by the submission of an ANDA.
The inspection of the Bengaluru facility took place between January 13-17, 2020. It resulted in zero observations and no Form 483 was issued.
Stock View:
Biocon Ltd is currently trading at Rs292.50 up by Rs2.05 or 0.71% from its previous closing of Rs290.45 on the BSE.
The scrip opened at Rs293.80 and has touched a high and low of Rs293.80 and Rs290.20 respectively. So far 9,98,631 (NSE+BSE) shares were traded on the counter.
The current market cap of the company is Rs34,854cr.
For Quick Trial – 8871888787
or mail us here - support@researchicon.com
or visit - http://www.researchicon.com/free-trial
إرسال تعليق